Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has been awarded a contract by Vizient, Inc., the nation’s largest member-driven healthcare performance improvement company. The agreement, effective starting August 1, 2022, covers the supply of Central Venous Access products, including Teleflex’s Arrow™ CVCs and Arterial Catheters.



This new agreement allows Vizient members to take advantage of special pricing and terms pre-negotiated by Vizient for Central Venous Access products. Teleflex, as the market leader in Central Venous Catheters (CVCs) with a market unit share of 60% in 2021 (IMS Data), is pleased to offer Vizient provider-customers one of the broadest portfolios of central access products available.

Teleflex’s Arrow™ Vascular Access Products are designed to equally benefit clinicians and patients, help protect against vascular access-related complications like infection, thrombosis, and tip malposition, and help clinicians follow independent third-party vascular access guidelines. The company’s Arrowg+ard Blue Plus™ CVCs feature broad-spectrum antimicrobial protection against fungi, gram-positive, and gram-negative bacteria, reducing Central Line-Associated Bloodstream Infections (CLABSI) by 67-100% (Rupp ME, Lisco SJ, Lipsett PA, et al., 2005; Lorente L, Lecuona M, Jimenez A, et al., 2014, 2016).



The contract includes access to Teleflex Arrowg+ard Blue Plus™ CVCs and Arrow™ ErgoPack™ Complete Systems. These solutions help healthcare systems comply with practice recommendations, standardize vascular access products across a healthcare system, maintain a high standard of patient care, and control costs and risks from infections (CDC Recommendations, SHEA Guidelines, INS Standards of Practice, and OSHA Bloodborne Pathogens Standard).

Teleflex, through its Arrow™ Catheters, has been at the forefront of vascular access innovation for more than four decades. The company’s commitment to quality, innovation, and customer satisfaction has positioned it as a trusted partner in the healthcare industry. This contract with Vizient further solidifies Teleflex’s market position and aligns with the company’s long-term growth strategy.

In conclusion, Teleflex’s contract with Vizient for the supply of Central Venous Access products is a significant milestone for the company. This agreement provides increased access to Teleflex’s products for a substantial portion of the nation’s acute care providers, further enhancing the company’s market share and revenue potential. As a leading provider of medical technologies, Teleflex continues to demonstrate its commitment to improving patient outcomes and driving innovation in the healthcare industry.